Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Update
Ensysce Biosciences (NASDAQ:ENSC) reported a sharp rise in short interest: 814,605 shares as of May 15, up from 52,730 on April 30, with about 5.7% of shares sold short and a days-to-cover ratio of 0.1 (based on average daily volume). The stock traded at $0.30. The company reported May 15 quarterly EPS of -$0.52 and revenue of $0.96M.
How this was made
The 30-second read
Why it matters
The main tradable signal is the magnitude of the short-interest increase plus very low days-to-cover, which can raise the probability of abrupt upside/downside moves even without new clinical/product news.
Market read
ENSC is highlighted for potential squeeze/volatility risk due to a 1,444.9% short-interest jump and 0.1 days-to-cover, despite weak recent profitability.
What to watch
The article lacks details on any new ENSC catalyst (trial readout, financing, FDA/regulatory action), so the move may reflect positioning rather than a fundamental re-rate.
Background
The piece summarizes ENSC’s May short-interest update and reiterates recent performance metrics and sell-side stance following its May 15 earnings release.
Ticker impact
Short interest jumped to 814,605 shares as of May 15, up 1,444.9% from April 30, with 5.7% of float sold short.
Near-term price action could be volatile, with downside still possible but squeeze dynamics increasing if buying pressure emerges.
Short interest increased dramatically and days-to-cover is extremely low (0.1), which can amplify price swings; however, the piece does not cite a new fundamental catalyst beyond prior earnings and ratings.
Market effects
For small-cap clinical-stage biopharma, extreme short-interest changes can quickly alter risk premia and trading liquidity.
Primarily a US microcap/biopharma positioning story; limited direct cross-market linkage implied.
Low—no global regulatory, trial, or partnership developments are described.
Counterpoint
A short-interest spike does not guarantee a squeeze; if fundamentals remain weak, shorts may be right and rallies can fade.
Key entities
- companyEnsysce Biosciences, Inc.
Clinical-stage biopharmaceutical company; the article reports a major May short-interest increase and references recent earnings and sell-side ratings.
